Cargando…

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy

Despite recent advances in multimodality therapy for glioblastoma (GB) incorporating surgery, radiotherapy, chemotherapy and targeted therapy, the overall prognosis remains poor. One of the interesting targets for GB therapy is the histone deacetylase family (HDAC). Due to their pleiotropic effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Everix, Liesbeth, Seane, Elsie Neo, Ebenhan, Thomas, Goethals, Ingeborg, Bolcaen, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967489/ https://www.ncbi.nlm.nih.gov/pubmed/37259375 http://dx.doi.org/10.3390/ph16020227

Ejemplares similares

A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma
por: Everix, Liesbeth, et al.
Publicado: (2022)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

The Path Toward PET-Guided Radiation Therapy for Glioblastoma in Laboratory Animals: A Mini Review
por: Donche, Sam, et al.
Publicado: (2019)

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
por: Miles, Xanthene, et al.
Publicado: (2021)

Assessment of the effect of therapy in a rat model of glioblastoma using [(18)F]FDG and [(18)F]FCho PET compared to contrast-enhanced MRI
por: Bolcaen, Julie, et al.
Publicado: (2021)

Radiopharmaceuticals for Cancer Imaging and Therapy
por: Bormans, Guy, et al.
Publicado: (2023)

New fluoroethyl phenylalanine analogues as potential LAT1-targeting PET tracers for glioblastoma
por: Verhoeven, Jeroen, et al.
Publicado: (2019)

Stroma Targeting Nuclear Imaging and Radiopharmaceuticals
por: Shetty, Dinesh, et al.
Publicado: (2012)

CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors
por: Yu, Jingjing, et al.
Publicado: (2023)

Radiopharmaceuticals for therapy
por: Knapp, F F (Russ), et al.
Publicado: (2016)

Cost-Effectiveness of [(18)F] Fluoroethyl-L-Tyrosine for Temozolomide Therapy Assessment in Patients With Glioblastoma
por: Baguet, Tristan, et al.
Publicado: (2019)

Technical feasibility of [(18)F]FET and [(18)F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
por: Verhoeven, Jeroen, et al.
Publicado: (2019)

HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013)

Radiopharmaceutical tracers for cardiac imaging
por: Manabe, Osamu, et al.
Publicado: (2017)

Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer
por: Beauregard, Jean-Mathieu
Publicado: (2022)

PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity
por: Sivapackiam, Jothilingam, et al.
Publicado: (2020)

Radiopharmaceuticals for PET imaging: issue A
por: Roivainen, Anne, et al.
Publicado: (2020)

Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma
por: Foster, Alexandra, et al.
Publicado: (2021)

Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
por: Pallares, Roger M., et al.
Publicado: (2022)

New SPECT and PET Radiopharmaceuticals for Imaging Cardiovascular Disease
por: Sogbein, Oyebola O., et al.
Publicado: (2014)

Can we produce an image of bacteria with radiopharmaceuticals?
por: Signore, A., et al.
Publicado: (2008)

Cerenkov Luminescence Tomography for In Vivo Radiopharmaceutical Imaging
por: Zhong, Jianghong, et al.
Publicado: (2011)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma
por: Nyakale, Nozipho, et al.
Publicado: (2023)

Perceptions of educators regarding the implementation of the health promotion programme manuals for children in schools in Makapanstad, South Africa
por: Peu, Doriccah, et al.
Publicado: (2015)

PET Radiopharmaceuticals
por: Shahhosseini, Soraya
Publicado: (2011)

Pharmacovigilance in radiopharmaceuticals
por: Kumar, Rishi, et al.
Publicado: (2016)

Obstacles and Recommendations for Clinical Translation of Nanoparticle System-Based Targeted Alpha-Particle Therapy
por: Kleynhans, Janke, et al.
Publicado: (2021)

Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi(8),Met(O(2))(11)]-Substance P
por: Suthiram, Janine, et al.
Publicado: (2023)

International Conference on Radiopharmaceutical Therapy: Speakers Abstracts
Publicado: (2012)

Radiopharmaceutical therapy in cancer: clinical advances and challenges
por: Sgouros, George, et al.
Publicado: (2020)

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
por: Barca, Cristina, et al.
Publicado: (2021)

Development and optimization of targeted radionuclide tumor therapy using folate based radiopharmaceuticals
por: Reber, Josefine Astrid
Publicado: (2015)

Targeted Auger electron-emitter therapy: Radiochemical approaches for thallium-201 radiopharmaceuticals
por: Rigby, Alex, et al.
Publicado: (2021)

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
por: El Fakiri, Mohamed, et al.
Publicado: (2021)

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy
por: Funeh, Cyprine Neba, et al.
Publicado: (2023)

Transport processes of radiopharmaceuticals and -modulators
por: Efferth, Thomas, et al.
Publicado: (2011)

Correction: Kinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine (FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET for the Fiscrimination between High-Grade Glioma and Radiation Necrosis in Rats
por: Bolcaen, Julie, et al.
Publicado: (2016)

Kinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine (FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET for the Fiscrimination between High-Grade Glioma and Radiation Necrosis in Rats
por: Bolcaen, Julie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q7fjrgion5vb59okvrlnsanoif